These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 2977262

  • 1. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y.
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [Abstract] [Full Text] [Related]

  • 2. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
    Metz R, Namer M, Adenis L, Audhuy B, Bugat R, Colombel P, Couette JE, Grise P, Khater R, LePorz B.
    Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
    [Abstract] [Full Text] [Related]

  • 3. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM, Ibbertson HK, Croxson MS, Harvey V, Boulton J, Knox BS.
    Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [Abstract] [Full Text] [Related]

  • 4. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M, Kotake T, Matsuda M, Okajima E, Osafune M, Sonoda T.
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [Abstract] [Full Text] [Related]

  • 5. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB, Griffiths K.
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C, Denis L.
    Am J Clin Oncol; 1988 Nov; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [Abstract] [Full Text] [Related]

  • 7. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA, Fernandez del Moral P, Plasman JW, Pull HC, van der Meijden AP, Debruyne FM, Hutchinson FG, Furr BJ.
    Eur Urol; 1990 Nov; 18 Suppl 3():22-5. PubMed ID: 2151271
    [Abstract] [Full Text] [Related]

  • 8. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
    Ryan PG, Peeling WB.
    Am J Clin Oncol; 1988 Nov; 11 Suppl 2():S169-72. PubMed ID: 2977272
    [Abstract] [Full Text] [Related]

  • 9. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR, Citrin DL, deHaan HA, Guinan P, Jordan VC, Kreis W, Scott M, Trump DL.
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [Abstract] [Full Text] [Related]

  • 10. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM, Denis L, Lunglmayer G, Mahler C, Newling DW, Richards B, Robinson MR, Smith PH, Weil EH, Whelan P.
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [Abstract] [Full Text] [Related]

  • 11. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [Abstract] [Full Text] [Related]

  • 12. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H, Varenhorst E, Svensson M, Kågedal B, Nordenskjöld B.
    Acta Oncol; 1988 Jun; 27(4):361-4. PubMed ID: 2974290
    [Abstract] [Full Text] [Related]

  • 13. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J.
    Wien Klin Wochenschr; 1990 Nov 09; 102(21):640-7. PubMed ID: 2148044
    [Abstract] [Full Text] [Related]

  • 14. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
    Murphy GP, Greco J, Huben R.
    Urology; 1987 Nov 09; 30(5):482-3. PubMed ID: 2960064
    [Abstract] [Full Text] [Related]

  • 15. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP, Greco JM, Chin JL, Huben RP, Scott M, deHaan HA.
    Urology; 1987 Feb 09; 29(2):185-90. PubMed ID: 2949417
    [Abstract] [Full Text] [Related]

  • 16. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ, Buck AC, Zwinck R, Peeling WB, Rees RW, Turkes A, Walker K, Griffiths K.
    Br J Urol; 1987 May 09; 59(5):436-42. PubMed ID: 2954605
    [Abstract] [Full Text] [Related]

  • 17. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L, Coste P, Richaud P, Lamarche P, Mage P, Bonichon F.
    Am J Clin Oncol; 1988 May 09; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [Abstract] [Full Text] [Related]

  • 18. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
    Emtage LA, Trethowan C, Hilton C, Kelly K, Blackledge GR.
    Am J Clin Oncol; 1988 May 09; 11 Suppl 2():S173-5. PubMed ID: 2977273
    [Abstract] [Full Text] [Related]

  • 19. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR, Grant J, Shalet SM, Howell A, Chowdhury SD, Weatherson T, Blacklock NJ.
    Br Med J (Clin Res Ed); 1985 Jan 19; 290(6463):185-7. PubMed ID: 3155636
    [Abstract] [Full Text] [Related]

  • 20. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
    Geldof AA, de Voogt HJ, Rao BR.
    Prostate; 1987 Jan 19; 11(3):281-90. PubMed ID: 2960958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.